CLINICAL STUDY: MYOCARDIAL INFARCTION AND ACUTE CORONARY SYNDROME
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm
Masahiro Mohri, MD, PhD*,*,
Hiroaki Shimokawa, MD, PhD*,
Yoji Hirakawa, MD*,
Akihiro Masumoto, MD* and
Akira Takeshita, MD, PhD, FACC*
* Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Manuscript received June 12, 2002;
revised manuscript received August 7, 2002,
accepted August 29, 2002.
* Reprint requests and correspondence: Dr. Masahiro Mohri, Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
mmohri{at}med.kyushu-u.ac.jp
OBJECTIVES: We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm.
BACKGROUND: Effective treatment of patients with angina who have normal coronary arteriograms (microvascular angina) has not yet been established. Rho-kinase–mediated calcium sensitization of the myosin light chain in smooth muscle cells has been implicated as substantially contributing to vascular hyperconstriction.
METHODS: We studied consecutive 18 patients with angina and normal epicardial coronaries in whom intracoronary acetylcholine (ACh) induced myocardial ischemia (ischemic electrocardiographic changes, myocardial lactate production, or both) without angiographically demonstrable epicardial coronary vasospasm. All patients underwent a second ACh challenge test after pretreatment with either saline (n = 5) or fasudil (4.5 mg intracoronarily, n = 13).
RESULTS: Myocardial ischemia was reproducibly induced by ACh in the saline group. In contrast, 11 of the 13 patients pretreated with fasudil had no evidence of myocardial ischemia during the second infusion of ACh (p < 0.01). The lactate extraction ratio (median value [interquartile range]) during ACh infusion was improved by fasudil pretreatment, from –0.16 (–0.25 to 0.04) to 0.09 (0.05 to 0.18) (p = 0.0125).
CONCLUSIONS: Fasudil ameliorated myocardial ischemia in patients who were most likely having coronary microvascular spasm. The inhibition of Rho-kinase may be a novel therapeutic strategy for this group of patients with microvascular angina.
|
Abbreviations and Acronyms
| | ACh | | acetylcholine | | ECG | | electrocardiogram/electrocardiographic | | ISDN | | isosorbide dinitrate |
|
This article has been cited by other articles:
|
|
|
|
 
Y. Kikuchi, S. Yasuda, K. Aizawa, R. Tsuburaya, Y. Ito, M. Takeda, M. Nakayama, K. Ito, J. Takahashi, and H. Shimokawa
Enhanced Rho-Kinase Activity in Circulating Neutrophils of Patients With Vasospastic Angina: A Possible Biomarker for Diagnosis and Disease Activity Assessment
J. Am. Coll. Cardiol.,
September 13, 2011;
58(12):
1231 - 1237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takagi, Y. Okamoto, S. Tomita, A. Sato, S. Yamaguchi, Y. Takuwa, and G. Watanabe
Intraradial administration of fasudil inhibits augmented Rho kinase activity to effectively dilate the spastic radial artery during coronary artery bypass grafting surgery
J. Thorac. Cardiovasc. Surg.,
August 1, 2011;
142(2):
e59 - e65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Satoh, Y. Fukumoto, and H. Shimokawa
Rho-kinase: important new therapeutic target in cardiovascular diseases
Am J Physiol Heart Circ Physiol,
August 1, 2011;
301(2):
H287 - H296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tsuburaya, S. Yasuda, T. Shiroto, Y. Ito, J. Y. Gao, K. Aizawa, Y. Kikuchi, K. Ito, J. Takahashi, H. Ishibashi-Ueda, et al.
Long-term treatment with nifedipine suppresses coronary hyperconstricting responses and inflammatory changes induced by paclitaxel-eluting stent in pigs in vivo: possible involvement of Rho-kinase pathway
Eur. Heart J.,
May 30, 2011;
(2011)
ehr145v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hartmann, J. Huisman, D. Bose, L. O. Jensen, P. Schoenhagen, G. S. Mintz, R. Erbel, and C. von Birgelen
Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: an update
Eur Heart J Cardiovasc Imaging,
April 1, 2011;
12(4):
313 - 321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Chimenti, P. Sale, R. Verardo, S. Cicalini, N. Petrosillo, M. A. Russo, F. Fedele, and A. Frustaci
High prevalence of intramural coronary infection in patients with drug-resistant cardiac syndrome X: comparison with chronic stable angina and normal controls
Heart,
December 1, 2010;
96(23):
1926 - 1931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Lanza and F. Crea
Primary Coronary Microvascular Dysfunction: Clinical Presentation, Pathophysiology, and Management
Circulation,
June 1, 2010;
121(21):
2317 - 2325.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q.-X. Li, Q.-Q. Fu, S.-W. Shi, Y.-F. Wang, J.-J. Xie, X. Yu, X. Cheng, and Y.-H. Liao
Relationship between plasma inflammatory markers and plaque fibrous cap thickness determined by intravascular optical coherence tomography
Heart,
February 1, 2010;
96(3):
196 - 201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J E van Velzen, J D Schuijf, F R de Graaf, G Nucifora, G Pundziute, J W Jukema, M J Schalij, L J Kroft, A de Roos, J H C Reiber, et al.
Plaque type and composition as evaluated non-invasively by MSCT angiography and invasively by VH IVUS in relation to the degree of stenosis
Heart,
December 15, 2009;
95(24):
1990 - 1996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Shiroto, S. Yasuda, R. Tsuburaya, Y. Ito, J. Takahashi, K. Ito, H. Ishibashi-Ueda, and H. Shimokawa
Role of Rho-Kinase in the Pathogenesis of Coronary Hyperconstricting Responses Induced by Drug-Eluting Stents in Pigs In Vivo
J. Am. Coll. Cardiol.,
December 8, 2009;
54(24):
2321 - 2329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lohn, O. Plettenburg, Y. Ivashchenko, A. Kannt, A. Hofmeister, D. Kadereit, M. Schaefer, W. Linz, M. Kohlmann, J.-M. Herbert, et al.
Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor
Hypertension,
September 1, 2009;
54(3):
676 - 683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Y. Mong and Q. Wang
Activation of Rho Kinase Isoforms in Lung Endothelial Cells during Inflammation
J. Immunol.,
February 15, 2009;
182(4):
2385 - 2394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V F Panoulas, S N Nikas, J P Smith, K M J Douglas, P Nightingale, H J Milionis, G J Treharne, T E Toms, M D Kita, and G D Kitas
Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis
Ann Rheum Dis,
November 1, 2008;
67(11):
1550 - 1556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Holvoet and P. Sinnaeve
Angio-Associated Migratory Cell Protein and Smooth Muscle Cell Migration in Development of Restenosis and Atherosclerosis
J. Am. Coll. Cardiol.,
July 22, 2008;
52(4):
312 - 314.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. K. Mishra
Variations in presentation and various options in management of variant angina
Eur J Cardiothorac Surg,
May 1, 2006;
29(5):
748 - 759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Loirand, P. Guerin, and P. Pacaud
Rho Kinases in Cardiovascular Physiology and Pathophysiology
Circ. Res.,
February 17, 2006;
98(3):
322 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Pepine, R. A. Kerensky, C. R. Lambert, K. M. Smith, G. O. von Mering, G. Sopko, and C. N. Bairey Merz
Some Thoughts on the Vasculopathy of Women With Ischemic Heart Disease
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3_Suppl_S):
S30 - S35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. K. Surks, N. Riddick, and K.-i. Ohtani
M-RIP Targets Myosin Phosphatase to Stress Fibers to Regulate Myosin Light Chain Phosphorylation in Vascular Smooth Muscle Cells
J. Biol. Chem.,
December 30, 2005;
280(52):
42543 - 42551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Vicari, B. Chaitman, D. Keefe, W. B. Smith, S. G. Chrysant, M. J. Tonkon, N. Bittar, R. J. Weiss, H. Morales-Ballejo, U. Thadani, et al.
Efficacy and Safety of Fasudil in Patients With Stable Angina: A Double-Blind, Placebo-Controlled, Phase 2 Trial
J. Am. Coll. Cardiol.,
November 15, 2005;
46(10):
1803 - 1811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Imoto, T. Hiro, T. Fujii, A. Murashige, Y. Fukumoto, G. Hashimoto, T. Okamura, J. Yamada, K. Mori, and M. Matsuzaki
Longitudinal Structural Determinants of Atherosclerotic Plaque Vulnerability: A Computational Analysis of Stress Distribution Using Vessel Models and Three-Dimensional Intravascular Ultrasound Imaging
J. Am. Coll. Cardiol.,
October 18, 2005;
46(8):
1507 - 1515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Shimokawa and A. Takeshita
Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine
Arterioscler Thromb Vasc Biol,
September 1, 2005;
25(9):
1767 - 1775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kishi, Y. Hirooka, A. Masumoto, K. Ito, Y. Kimura, K. Inokuchi, T. Tagawa, H. Shimokawa, A. Takeshita, and K. Sunagawa
Rho-Kinase Inhibitor Improves Increased Vascular Resistance and Impaired Vasodilation of the Forearm in Patients With Heart Failure
Circulation,
May 31, 2005;
111(21):
2741 - 2747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yada, H. Shimokawa, O. Hiramatsu, T. Kajita, F. Shigeto, E. Tanaka, Y. Shinozaki, H. Mori, T. Kiyooka, M. Katsura, et al.
Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo
J. Am. Coll. Cardiol.,
February 15, 2005;
45(4):
599 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hirayama, Y. Hata, Y. Noda, M. Miura, I. Yamanaka, H. Shimokawa, and T. Ishibashi
The Involvement of the Rho-Kinase Pathway and Its Regulation in Cytokine-Induced Collagen Gel Contraction by Hyalocytes
Invest. Ophthalmol. Vis. Sci.,
November 1, 2004;
45(11):
3896 - 3903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Crea and G. A Lanza
Angina pectoris and normal coronary arteries: cardiac syndrome X
Heart,
April 1, 2004;
90(4):
457 - 463.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Force, K. Kuida, M. Namchuk, K. Parang, and J. M. Kyriakis
Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease
Circulation,
March 16, 2004;
109(10):
1196 - 1205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Bao, E. Hu, L. Tao, R. Boyce, R. Mirabile, D. T Thudium, X.-l. Ma, R. N Willette, and T.-l. Yue
Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury
Cardiovasc Res,
February 15, 2004;
61(3):
548 - 558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. K. Surks, C. T. Richards, and M. E. Mendelsohn
Myosin Phosphatase-Rho Interacting Protein: A NEW MEMBER OF THE MYOSIN PHOSPHATASE COMPLEX THAT DIRECTLY BINDS RhoA
J. Biol. Chem.,
December 19, 2003;
278(51):
51484 - 51493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
